Tecemotide is an active immunotherapeutic agent targeting a cell surface glycoprotein, mucin 1 (MUC1), and is highly expressed in various malignant tumors and is associated with cellular growth, invasion, and metastasis (43–45). Here, MUC1 is linked to cancer.